Disease relevance of Ductus Arteriosus, Patent

• CONCLUSIONS: In extremely-low-birth-weight infants, prophylaxis with indomethacin does not improve the rate of survival without neurosensory impairment at 18 months, despite the fact that it reduces the frequency of patent ductus arteriosus and severe periventricular and intraventricular hemorrhage [1].
• CONCLUSIONS: Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria [2].
• BACKGROUND: The prophylactic administration of indomethacin reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage in very-low-birth-weight infants (those with birth weights below 1500 g) [1].
• Sepsis and indomethacin failure in premature infants with symptomatic patent ductus arteriosus [3].
• Associated lesions included ventricular septal defect in 7, patent ductus arteriosus in 12, coarctation of the aorta in 8, pulmonary stenosis in 3, atrioventricular canal in 2 and miscellaneous lesions in 3 cases [4].

Psychiatry related information on Ductus Arteriosus, Patent

• The chromosomal anomaly in this child was associated with a unique congenital syndrome including HBL, atrial septal defect, ventricular septal defect, patent ductus arteriosus, mental retardation, and seizures [5].
• OBJECTIVE: To determine in preterm infants with a patent ductus arteriosus (PDA) the effect of indomethacin treatment on spontaneous motor activity [6].

High impact information on Ductus Arteriosus, Patent

• Ibuprofen versus indomethacin for closure of patent ductus arteriosus [7].
• Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus [8].
• Promotion of patent ductus arteriosus by furosemide [9].
• Females with PH present with epilepsy and other signs, including patent ductus arteriosus and coagulopathy, while hemizygous males die embryonically [10].
• Chloroquine as prostaglandin antagonist in treatment of patent ductus arteriosus [11].

Chemical compound and disease context of Ductus Arteriosus, Patent

• Prophylactic indomethacin for patent ductus arteriosus [12].
• Ibuprofen and patent ductus arteriosus [13].
• In a preliminary study chloroquine has been successfully used to close patent ductus arteriosus in three infants [14].
• CONCLUSION: PGE2-mediated depression of Ca(2+)-activated force in the smooth muscle of the ductus arteriosus may play a role in the maintenance of a patent ductus arteriosus in the fetus [15].
• Transvenous closure is described of the patent ductus arteriosus with a conical device that consists of polyurethane foam mounted on a stainless steel frame [16].

Biological context of Ductus Arteriosus, Patent

• Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus [17].
• To determine the effect of i.v. indomethacin on cerebral intracellular oxygenation, as judged by changes in the concentration of oxidized cytochrome oxidase, studies were performed using near-infrared spectroscopy on 15 infants of 23 to 29 wk gestation, aged 8 to 30 d, who required the drug for closure of a patent ductus arteriosus [18].
• Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus [19].
• Characteristic congenital heart diseases in trisomy 18 were polyvalvular disease in 100%, membranous ventricular septal defect, patent ductus arteriosus, and high take-off of the right coronary ostium [20].
• Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus [21].

Anatomical context of Ductus Arteriosus, Patent

• The only potentially significant false negative findings were one ventricular septal defect, two small atrial septal defects, one mitral valve anomaly, one tricuspid valve anomaly, three instances of patent ductus arteriosus and four instances of persistent left superior vena cava [22].
• From Aug. 1, 1991, to May 31, 1992, we evaluated 47 transmissional studies (diagnoses: 24 normal, 8 patent ductus arteriosus, 6 ventricular septal defect, 2 pulmonary stenosis, 1 ventricular septal defect with interrupted aortic arch, and 6 miscellaneous) [23].
• Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus [24].
• These observations are also consistent with the findings that preterm infants have an increased incidence of patent ductus arteriosus and that indomethacin can constrict the ductus arteriosus in preterm infants [25].
• Our results suggest that in infants with patent ductus arteriosus the left atrium is the main source of ANP [26].

Gene context of Ductus Arteriosus, Patent

• These results suggest that neonatal death is at least partly due to patent ductus arteriosus and that the EP4 receptor plays a role in regulation of the patency of this vessel [27].
• CHDs were patent ductus arteriosus, atrial and ventricular septal defects, partial anomalous pulmonary venous return, transposition of the great arteries, atrioventicular canal, and rare lesions with systemic-to-pulmonary shunts [28].
• Molecular determinants of atrial and ventricular septal defects and patent ductus arteriosus [29].
• To observe the association of MTHFR gene C677T locus polymorphism with occurrence of congenital heart defects (CHDs), 21 patients with atrial septal defect (ASD), 35 patients with patent ductus arteriosus (PDA), one patient with both conditions combined, and their biological parents were collected as the case group [30].
• M-mode lacked sensitivity for ventricular septal defect (VSD) and patent ductus arteriosus (PDA) [31].

Analytical, diagnostic and therapeutic context of Ductus Arteriosus, Patent

• More indomethacin-exposed infants with a patent ductus arteriosus required surgical ligation because of either a lack of initial response or a reopening of the duct after postnatal indomethacin therapy (50 percent vs. 20 percent of the unexposed infants, P = 0.05) [32].
• Near infrared spectroscopy was used to investigate the effects of intravenously administered indomethacin (0.1-0.2 mg/kg) on cerebral haemodynamics and oxygen delivery in 13 very preterm infants treated for patent ductus arteriosus [33].
• In neonates, a patent ductus arteriosus as well as treatment with indomethacin or extracorporeal membrane oxygenation (ECMO) leads to an increase in volume of distribution and a decrease in clearance [34].
• Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus [35].
• Gentamicin clearance was decreased in the patent ductus arteriosus group vs. the control group (40.02 vs. 44.73 mL/kg/hr; p < .0108) [36].

References